These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 483271)

  • 21. Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism.
    Dupe RJ; English PD; Smith RA; Green J
    Thromb Haemost; 1984 Apr; 51(2):248-53. PubMed ID: 6234676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the interaction of group A streptococci with fibrinogen, streptokinase and plasminogen.
    Wang H; Lottenberg R; Boyle MD
    Microb Pathog; 1995 Mar; 18(3):153-66. PubMed ID: 7565010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acoustic determination of performance and equivalence of plasminogen activators.
    Ghazali M; Hayward GL
    Anal Bioanal Chem; 2008 Nov; 392(5):897-902. PubMed ID: 18759103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of plasma specific fibrin degradation products during thrombolytic therapy in patients with thrombo-embolism.
    Faivre R; Mirshahi M; Ducellier D; Soria C; Soria J; Mirshahi M; Kieffer Y; Bassand JP; Caen J; Maurat JP
    Thromb Res; 1988 May; 50(4):583-9. PubMed ID: 3413720
    [No Abstract]   [Full Text] [Related]  

  • 25. Problems of resistant thrombolysis and early recurrent thrombosis in streptokinase therapy.
    Dhall DP; Dawson AA; Mavor GE
    Surg Gynecol Obstet; 1978 Jan; 146(1):15-20. PubMed ID: 618486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase.
    Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR
    Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Do thrombolytic agents prevent postphlebitis thromboembolism?].
    Trübestein G
    Haemostasis; 1986; 16 Suppl 4():40-53. PubMed ID: 3490419
    [No Abstract]   [Full Text] [Related]  

  • 28. The hematologic consequences of thrombolytic therapy.
    Fletcher AP; Alkjaersig NK
    Prog Hematol; 1986; 14():183-200. PubMed ID: 2935903
    [No Abstract]   [Full Text] [Related]  

  • 29. Concepts of clot lysis.
    Francis CW; Marder VJ
    Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Samama M; Conard J; Verdy E; van Dreden P; Nguyen G; Combrisson A; Acar J
    Drugs; 1987; 33 Suppl 3():268-74. PubMed ID: 3315605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
    Sakai M; Watanuki M; Matsuo O
    Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 33. [The progress of a fibrinolytic therapy with streptokinase, urokinase and warfarin in a thoroughbred with intermittent lameness with special reference to resonance thrombography].
    Pause B; Nolte I; Geiss V; Mayer H; Lasch HG
    Tierarztl Prax; 1988; 16(4):377-83. PubMed ID: 3222790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR; Miletich JP; Sobel BE; Jaffe AS
    Thromb Res; 1988 Jun; 50(5):707-17. PubMed ID: 3137687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The influence of 6-AHA on the fibrin clot degradation initiated by streptokinase in normal and alpha 2-antiplasmin-deficient plasma.
    Andrianov SL; Gutsalo AE
    Ukr Biokhim Zh (1978); 1996; 68(4):26-7. PubMed ID: 9226814
    [No Abstract]   [Full Text] [Related]  

  • 36. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
    Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
    Thromb Haemost; 1996 Sep; 76(3):339-43. PubMed ID: 8883267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biological effects of the administration of an equimolar streptokinase-plasminogen complex in man.
    Verstraete M; Vermylen J; Holleman W; Barlow GH
    Thromb Res; 1977 Aug; 11(2):227-36. PubMed ID: 905974
    [No Abstract]   [Full Text] [Related]  

  • 39. A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.
    Reed GL; Houng AK; Liu L; Parhami-Seren B; Matsueda LH; Wang S; Hedstrom L
    Proc Natl Acad Sci U S A; 1999 Aug; 96(16):8879-83. PubMed ID: 10430864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Plasmin formation in a fibrin network].
    Kotschy M; Knapik M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1971; 95(2):167-73. PubMed ID: 4106005
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.